Olivier Bénichou

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

Clemens Becker, Stephen R. Lord, Stephanie A. Studenski et al. · The Lancet Diabetes & Endocrinology · 2015 · 367 citations

Life Sciences, Geriatric Medicine, Immunology +8

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Mark C. Genovese, Maria Greenwald, Chul‐Soo Cho et al. · Arthritis & Rheumatology · 2014 · 205 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto et al. · The Journal of Rheumatology · 2017 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Tibial coverage, meniscus position, size and damage in knees discordant for joint space narrowing – data from the Osteoarthritis Initiative

K. Bloecker, Ali Guermazi, W. Wirth et al. · Osteoarthritis and Cartilage · 2012 · 117 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Olivier Bénichou, Tamer Coşkun, Malgorzata D. Gonciarz et al. · Cell Metabolism · 2023 · 95 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14